On Friday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) opened lower -0.89% from the last session, before settling in for the closing price of $39.26. Price fluctuations for XENE have ranged from $35.53 to $50.99 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 44.88% over the last five years. Company’s average yearly earnings per share was noted -13.44% at the time writing. With a float of $73.30 million, this company’s outstanding shares have now reached $75.79 million.
The firm has a total of 259 workers. Let’s measure their productivity. In terms of profitability, gross margin is 60.8%, operating margin of -4749.37%, and the pretax margin is -3974.61%.
Xenon Pharmaceuticals Inc (XENE) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xenon Pharmaceuticals Inc is 3.86%, while institutional ownership is 97.16%. The most recent insider transaction that took place on Jan 24 ’25, was worth 903,214. In this transaction PRESIDENT & CEO of this company sold 22,468 shares at a rate of $40.20, taking the stock ownership to the 31,302 shares. Before that another transaction happened on Jan 27 ’25, when Company’s PRESIDENT & CEO sold 16,315 for $40.50, making the entire transaction worth $660,806. This insider now owns 31,302 shares in total.
Xenon Pharmaceuticals Inc (XENE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.82% during the next five years compared to -10.87% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Check out the current performance indicators for Xenon Pharmaceuticals Inc (XENE). In the past quarter, the stock posted a quick ratio of 22.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.81, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -3.73 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Analysing the last 5-days average volume posted by the [Xenon Pharmaceuticals Inc, XENE], we can find that recorded value of 0.38 million was lower than the volume posted last year of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 48.06%. Additionally, its Average True Range was 1.31.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 22.09%, which indicates a significant decrease from 34.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 19.50% in the past 14 days, which was lower than the 34.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.92, while its 200-day Moving Average is $40.32. Now, the first resistance to watch is $39.68. This is followed by the second major resistance level at $40.45. The third major resistance level sits at $41.06. If the price goes on to break the first support level at $38.30, it is likely to go to the next support level at $37.69. Should the price break the second support level, the third support level stands at $36.92.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
There are currently 76,240K shares outstanding in the company with a market cap of 2.97 billion. Presently, the company’s annual sales total 0 K according to its annual income of -182,390 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -62,790 K.
